The UK and US have reached a landmark trade agreement that will guarantee zero levies on British drug products going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to boost funding on drugs through the public health system. This move guarantees that tariffs on these vital goods will remain at nothing for a period of the next three years.
This development comes after previous warnings to significantly raise import taxes on branded pharmaceutical imports, with potential rates discussed up to one hundred percent.
"This arrangement with the UK strengthens the international landscape for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," a statement declared.
Commercial Importance
Medicines represent one of the UK's largest goods shipped to the United States, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the year prior to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This value represented 17.4% of all goods exports in that period.
"This agreement secures jobs, boosts investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Detailed NHS Changes
The pact involves several specific commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at 15%. Last year, repayments were more than twenty percent.
Recent Tensions
This agreement follows a ongoing row between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by claims that US customers were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or cancelled, while substantial investments have been pledged toward projects in the United States.
One official stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
